Teva to present data demonstrating uzedy™ (risperidone) extended-release injectable suspension significantly prolonged time to impending relapse for adults with schizophrenia at the american psychiatric association's 2023 annual meeting

Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced that four studies across its neuroscience portfolio will be presented during the american psychiatric association's (apa) 2023 annual meeting taking place on may 20-24, 2023. abstracts include data for uzedy (risperidone) extended-release injectable suspension for subcutaneous use, which was recently approved by the fda for th.
TEVA Ratings Summary
TEVA Quant Ranking